Skip to main content
. 2015 Jul 3;6(8):767–775. doi: 10.7150/jca.11833

Fig 4.

Fig 4

RGS17 is a target gene of miR-32. (A) The predicted binding site of miR-32 in 3'UTR of RGS17. (B) Detection of miR-32 expression in breast cancer tissues (T) and corresponding non-cancerous tissues (N) by qRT-PCR. miR-32 expression level was calculated by 2-ΔCt methods and normalized to U6 small nuclear RNA. **p<0.01, ***p<0.001. (C) Expression of miR-32 in cell lines was detected by qRT-PCR. ***p<0.001. (D) Detection of miR-32 expression in breast cancer cell line (ZR-73-30). **p<0.01. (E) Expression of RGS17 in cells transfected with miR-32 was detected by western blot. (F) Cell migration was analyzed by wound-healing assay in cells transfected with indicated constructs. Data represent the mean ± SD of experiments performed in triplicate. *p<0.05, ****p<0.0001. (G) CCK-8 assay was performed to detect cell proliferation. *p<0.05 (Control vs. miR-32), ♯p<0.05 (miR-32 vs. miR-32+RGS17). (H) Boyden chamber assay was photographed and migrated/invaded cell numbers of three parallel experiments were counted to calculate average number of cells that transmigrated. *p<0.05, **p<0.01.